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BACKGROUND: Clinical trials are probably the most informative experiments to help understanding 
of multiple sclerosis (MS) biology. Recent successes with CD20-depleting antibodies have focussed 
attention towards B cell subsets as important mediators in MS.  
METHOD: We report and review the trial of tabalumab (NTC00882999), which inhibits B cell Activation 
Factor (BAFF), and contrast this with inhibition of A Proliferation-Inducing Ligand (APRIL) and BAFF 
using atacicept (NCT00642902).   
RESULTS: Both tabalumab and atacicept induce depletion of mature B cells and inhibit antibody-
formation, but they fail to deplete memory B cells and do not inhibit relapsing MS. Atacicept is reported 
to augment memory B cell responses and may precipitate relapse suggesting the importance of APRIL. 
However, BAFF inhibition can enhance peripheral blood memory B cell responses, which was not 
associated with augmented relapse. 
CONCLUSIONS: Although other interpretations are possible, this data further supports the hypothesis 
that memory B cells may be of central importance in relapsing MS, as they are the major CD20+ B 
cell subset expressing APRIL receptors. It also suggests that quantitative and/or qualitative differences 
in B cell responses or other factors, such as immune-regulatory effects-associated with APRIL, may 
be important in determining whether MS reactivates following neutralization of peripheral B cell 



























Multiple sclerosis (MS) is the major immune-mediated demyelinating disease of the central nervous 
system (CNS). Although one can look to biology and animal models to understand the pathogenesis 
of MS, the most informative experiment is the human clinical trial. A successful trial or a negative 
result from a well-constructed study are informative. Although considered to be a T-cell mediated 
disease, response to therapy may suggest that B cell-selective agents exhibit control of relapsing MS 
[1].  It has been shown that CD20-B cell depleting agents control MS and inhibit lesion formation and 
clinical relapse [2].  Therefore, it is not surprising that targeting B cell survival factors was considered 
as an alternative approach to target autoimmunity [3-5]. As shown here, these have failed to inhibit 
MS, indicating that they are not adequately targeting the essential pathogenic disease mechanisms.  
 
Positive clinical trials point towards memory B cells as important mediators in MS. Although 
attention has focused on the importance of T cells in MS pathogenesis, all agents that currently inhibit 
MS can limit entry of memory B cells into the CNS [1,6]. This hypothesis is potentially consistent with 
the aetiology, pathology and importantly the treatment response-hierarchy in MS [1,6]. As such, 
memory B cells could directly trigger pathology or may act indirectly, such as via activating pathogenic 
T cells [1,6]. Whilst CD20-specific therapy suggests a plasma cell-independent action, this could also 
involve direct actions on T cells, via depletion or alterations in T cell regulatory balance [1,6,7].  
 
Negative clinical trials point towards memory B cells as important mediators in MS. To date 
there have been three MS-related trials of B cell-restricted survival factors relating to the tumour 
necrosis factor superfamily of ligands and B cell-restricted receptors (Figure 1) [3-5]. As reported and 
reviewed here, these fail to reduce memory B cells and have failed to control relapsing MS. 
 
The tumour necrosis factor superfamily of B cell-related maturation and survival factors. B 
cell activating factor (BAFF/Tumour necrosis factor superfamily member 13B (TNFS13B/CD257)) 
promotes maturation and survival of B cells and is the dominant homeostatic regulator of peripheral 
B cell pools [8]. This binds and acts via the transmembrane activator, calcium modulator and 
cyclophilin ligand interactor (TACI/TNFSR13C/CD267) receptor, the BAFF-receptor (BAFF-
R/TNFSR13B/CD268) and the B cell maturation antigen (BCMA/TNFSR17/CD269) (Figure 1) [8]. 
However, BAFF binds to the BAFF-R with significantly higher affinity than BCMA [8]. This latter receptor 
is also bound by a proliferation-inducing ligand (APRIL/ TNFSF13/CD256). APRIL acts on TACI, BCMA 
but, not BAFF-R and binds to BMCA with a higher affinity than BAFF (Figure 1) [8,9]. Both BAFF and 
APRIL are produced from membrane bound molecules by cleavage, which occurs in the Golgi with 
APRIL, to produce homotrimers and oligomers [8,9]. APRIL can also bind to heparin sulphate 
proteoglycans (HSPG) to create oligomerization, which serves to increase APRIL signalling [9]. 
Similarly, BAFF undergoes oligomerization to form 60mers that promotes the engagement of many 
receptors at a single site and is required for activation of TACI [10]. The biology is further complicated 
by the occurrence of alternative-splicing variants for the different receptors and the presence of 
soluble decoy receptors that can be shed following cleavage of the receptors [11]. These molecules 
mediate a variety of different functions within the B cell lineage and have been targeted to create a 





Inhibition of soluble BAFF does not inhibit or augment multiple sclerosis. Tabalumab is a 
human IgG4 monoclonal antibody that neutralizes membrane and soluble BAFF [5,12] 
[NCT008829999]. This contrasts with belimumab that is a human IgG1 monoclonal antibody, licenced 
for the treatment of systemic lupus erythematosus, which targets soluble BAFF, notably the trimeric 
BAFF molecule [13]. Atacicept is a fusion protein of TACI and constant regions of human IgG1 that 
blocks BAFF and APRIL [3,4].  
 
Whilst the data for the atacicept trial in MS (Table 1. NCT00642902. Treated with 0, 25, 75, 150mg 
atacicept within about a median of 6.9-8.6 years from first symptom) has been reported [3, 4], the 
data relating to the tabalumab trial (Table 1. Treated Q4W with 0, 4, 12, 40 or 120mg antibody from 
a median of 7.4-9.4 years after first symptom) has not been published. However, the conclusions and 
tabulated data (Table 1A) can be found in the public domain [5], [NCT0088299999]. Of the 245 people 
with MS randomised to tabalumab, 197 (80%) completed the study. The primary endpoint was the 
mean total cumulative number of gadolinium-enhancing (Gd+) magnetic resonance imaging lesions 
during the study. There were 1.521 and 1.758 lesions, averaged over weeks 12-24, in all-tabalumab 
and placebo groups, respectively, and the differences overall, or between any of the tabalumab groups 
and placebo, were not statistically significant [5]. Furthermore, there was no indication of any 
treatment influence on secondary outcomes. Notably there was no difference in the accumulation of 
T2 lesions or annualised relapse rate (Table 1A). Importantly, there was no evidence for enhanced 
numbers of relapses following tabalumab treatment (Table 1A). This contrasts with that reported 
following atacicept treatment [Table 1B], which led to the trial-termination [3,4].   
 
Although the patient demographics between these two phase II trials are not identical (Table 1), they 
are similar and given that the apparent worsening was seemingly evident in the atacicept optic neuritis 
trial [4], could suggest that the tabalumab trial was sufficiently large to detect an enhanced relapse 
frequency. Indeed, relapse of MS was a reported adverse effect in the tabalumab report, so it is 
unlikely that an enhanced relapse-frequency was missed.  
 
The adverse events of atacicept have been reported [3], as have those of tabalumab in trials not 
related to MS [12]. In MS, the proportion of people reporting at least one treatment-emergent adverse 
event, serious adverse event, and follow-up emergent adverse event was higher in the all-tabalumab 
group than placebo (68.1% (n=143) vs 48.6% (n=17), 11% (n=23) vs 5.7% (n=2), and 41.9% 
(n=88) vs 34.3% (n=12), respectively]; however, this was not dose-dependent [5]. Fatigue was the 
only consistent adverse event reported to occur in more than 5% of the groups (5.6%-11.4%) 
following tabalumab treatment compared to the placebo (0%). The data therefore suggests that 
tabalumab was inactive at the doses tested in MS. This would either suggest that the apparent 
worsening of MS following atacicept administration [3] was due to a combination of BAFF and APRIL 
inhibition or that blockade of APRIL was the major problem. 
 
Expression profile of B cell-specific survival factors. Examination of BAFF and APRIL receptor 
gene expression within human B cell lineages indicate that BAFF-R is present on all peripheral B cell 
subtypes (Figure 2. Data extracted from the primary cell atlas [14] database. www.biogps.org). 




consistent with the reported levels of protein using flow cytometry [15,16]. Although BAFF-R was 
detected on plasma cells (Figure 2) consistent with the influence of belimumab of loss of peripheral 
plasma cells [13], in some instances, notably in the bone marrow BAFF-R can be lost from plasma 
cells [15]. This expression profile is consistent with the role of BAFF and BAFF-R as a positive regulator 
and survival factor for peripheral B cells [8]. The TACI receptor, based on relative gene levels, was 
most expressed on human memory B and plasma cells and at lower levels on other cell types (Figure 
2), again consistent with protein expression, where it has been shown that TACI is upregulated during 
B cell activation [15,16]. BCMA message was expressed largely by plasma cells, again consistent with 
the reported expression of BCMA protein (Figure 2) [15,16]. These distributions may be different from 
that found in mice, notably related to the APRIL receptors, perhaps accounting for some species 
differences [8]. However, that human deficiency of TACI/TNFRSF13B can lead immunodeficiency, with 
a diminished memory B cell phenotype notably within the immunoglobulin (Ig) class-switched B cells, 
suggests the importance of this receptor to memory B cell biology [17]. 
  
Blockade of BAFF is associated with depletion of mature B cells and not memory B cells. 
Mutations in BAFF or the BAFF-R in mice cause B-cell lymphopenia and antibody deficiency [8,18]. 
Genetic deletion of human BAFF-R can lead to arrested B cell development at the 
transitional/immature to mature B cell stage, such that the numbers of all subsequent B-cell stages 
are severely reduced [18]. Following neutralization of BAFF, with tabalumab, there was a depletion of 
CD27-, IgD- cells, which were termed immature/transitional B cells by the sponsor (Figure 3). 
However, this must carry the proviso that in the absence of the flow cytometry methodology used in 
this study, the CD19+, CD27-, IgD- B cells may represent CD27- memory B cells [19, 20].  However, 
cells described as transitional B cells, detected using CD10, CD19, CD24, CD38, are depleted by 
tabalumab [21]. Long-lived plasma cells survival is likewise dependent on BAFF [22], consistent with 
the capacity of BAFF-inhibition to limit antibody production and reduce plasma cell numbers in humans 
[13,21]. However, depletion of naïve/mature B cells by tabalumab was the most evident feature on 
the analysis of B cell levels in MS [Figure 3]. Likewise, marked mature B cell depletion is a consistent 
effect following neutralization of BAFF with tabalumab [20] and belimumab [13] in other studies. This 
subset was also markedly (50-60%) depleted by atacicept in MS [3], consistent with that found 
elsewhere [23]. 
 
Although the data on memory B cell effects of atacicept in MS were not reported [3], it has been 
shown that atacicept induces a marked but transient increase in memory B cells, in the blood [23]. 
This has been suggested to be a possible reason for disease augmentation following atacicept 
treatment in MS [1]. This could be contrasted with some reports that the memory B cell response, 
notably the class-switched memory B cell response, is unaffected by neutralization of BAFF [13,24], 
as a possible reason for the disparity between BAFF and BAFF/APRIL inhibition. However, this now 
appears to be a too simplistic explanation.  Although raw data was not available to perform statistics, 
blockade of BAFF by tabalumab induced a dose-dependent increase in memory B cells during 
treatment (Figure 3). This would be significant based on reported reference B cell subset levels [25]. 
Whilst many tabalumab studies have focussed on the mature and plasma cell depleting capacity [12, 
21], augmentation of memory B cell responses within peripheral blood and lymphoid tissue has been 




notably within the class-switched subset [13, 26]. This occurs rapidly following initiation of treatment 
and is then often followed by slow depletion over 52 weeks during treatment [24]. The unswitched 
memory B cell subset may decline to about -15% of baseline levels during 12-months of belimumab 
treatment and -52% of baseline levels at 18-months of treatment [13,26]. Whereas class-switched 
memory B cells appear not to be rapidly-depleted over 18 months of treatment and increase in some 
individuals [26]. This is perhaps consistent with the survival of class-switched memory B cells, despite 
the lack of BAFF [22]. However, with time and after several years of belimumab treatment it seems 
that even Ig class-switched memory B cells are depleted [26]. This suggests that mature B cell 
depletion eventually exhausts part of the downstream memory B cell [26]. Furthermore, it should not 
be surprising that peripheral blood B cell numbers may not predict treatment response, as relapsing 
autoimmunity can occur in people without a significant peripheral blood memory B cell pool, as shown 
following CD20-depletion therapy [6]. Whilst some of the enhanced memory B cell activity, seen here, 
could relate to anti-drug antibody responses, as they can and do occur with low frequency with these 
agents [12], in this MS study these were not detected against tabalumab (Table 1A). This suggests 
that other factors are important in the memory B cell responses. Indeed, as memory B cells are 
reported to be relatively insensitive to the survival activities of BAFF and APRIL [22,24], it suggests 
that other factors, such as loss of regulation may contribute to the increased memory cell numbers. 
This could be a central factor in the possible differences in response between tabalumab and atacicept. 
As such APRIL can exhibit negative regulatory activity that may be involved in the generation of 
regulatory B and T cells [27, 28]. Furthermore, it is known that TACI stimulation may regulate some 
of the activities of human B cells simulated via the BAFF-R [9]. Loss of regulatory activity may then 
allow disease breakthrough, in some individuals, but this requires further study.  
 
Whilst we have focused on B cell-related effects, it is important to recognise that other activities of 
BAFF and APRIL inhibition, such as influences on plasmacytoid dendritic cells, astrocytes or even T 
cells, may account for the biological effects of treatment in MS [29-31]. Although APRIL targeting 
agents have been generated [9], they are unlikely to be investigated in MS following the problems 
recognised with atacicept. However, the data presented here further indicate the importance of 
reporting negative clinical studies. 
 
The primary endpoint of both the tabalumab and atacicept indicated no treatment effect. 
Whilst this study attempts to dissect biological differences to explain variation between atacicept and 
tabalumab in terms of clinical effect, it should be kept in mind that both trials concluded that there 
were no treatment effects, based on their primary magnetic resonance imaging-based clinical 
outcomes [3,5]. The initial lesion loads appear to be similar between the studies reported here (Table 
1). It is of interest therefore, that although the frequency of relapse is considered to be enhanced by 
atacicept [3], there appears to be little difference in the annualised relapse rate between atacicept 
and tabalumab treatment and the relapse rates found in the tabalumab trial and the placebo arm of 
the atacicept trial (Table 1). Furthermore, the frequency of conversion to MS in the optic neuritis 
(inflammation of the optic nerve that may be idiopathic of a sign of MS) trial of atacicept (Treated with 
150mg atacicept within a median of about 0.2 years from onset) was not statistically different between 
drug (6/17 people [35.3%]) and placebo (3/17 people [17.6%)]. Chi-squared with Yates correction 




simply have been inactive at controlling relapsing MS. Never the less, if the idea about the central 
importance of memory B cells is correct, then a more focused approach to target these may be feasible 
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FIGURE 1. BAFF/APRIL-related ligands and receptors for B cell control.  Potential binding activities 
and functions of BAFF and APRIL related molecules [13]. The positive effects of TACI may be mediated 
by APRILTACI/HSPG interactions and negative regulation may be via BAFF/TACI interactions.  
 
FIGURE 2. Gene expression of B cell growth factor receptors by B cell subsets. Relative gene 
expression of BAFF-R (TNFRSF13C) probe set 1552892_at, TACI [TNFRSF13B] probe set 1423182_at 
and BCMA (TNFRSF17) probe 206641_at using Affymetrix Human Genome U133 Plus 2.0 expression 
arrays in the primary cell atlas at www.biogps.org [14]. The results represent the mean ± SD 
normalised arbitrary units of fluorescence intensity in the primary cell atlas [14]. The baseline was set 
at the level as the median expression [72.4, 82.4, and 12.4 respectively] of whole primary cell data 
set. 
 
FIGURE 3. The B cell depleting capacity of tabalumab treatment. People with clinically-definite MS 
were treated with placebo or various doses of tabalumab administered every 4 weeks (Q4W) for 24 
weeks. Peripheral blood was collected and stained to detect (CD19+, CD27+,IgD-) cells termed 
transitional/immature cells by the sponsor, although they may represent double negative memory 
cells if no additional markers were used in their detection[19,21], mature (CD19+,CD27-,IgD+), 
unswitched memory (CD19+,CD27+,IgD+) or class-switched memory (CD19+,CD27+,IgD-) B cells 
and the mean ± standard error of the mean change in cell number (cells/μl) was reported. Data were 
extracted from www.clinicaltrials.gov (NCT00882999). Baseline values were not reported but 
reference median B cell number for 26-50 year olds is about:  4 immature/transitional 
(CD24+,CD38+) B cells cells/µl, 131 mature (CD27,IgD+) B cells/µl, 35 Ig non-switched 
(CD27+,IgD+)/µl memory B cells, 29 Ig class-switched (CD27+,IgD-) memory B cells/µl and 7 












Table 1. Demographics and treatment outcomes in phase II tabalumab and atacicept trials in MS 
Table 1A Dose of tabalumab 
Tabalumab NCT00882999 trial Placebo 4mg  12mg  40mg  120mg 
Number 
Age (Year) 
Sex (% Female) 
Time from first symptom (years) 
Mean Relapses past year  
Baseline No. T1 Gd+ lesions 
Volume T2 lesions (mL)  
 
No. T1 Gd+ lesion per scan 
No. New T2 lesions at 24 week 
No New T2 lesions at 48 week 
EDSS at week 24  
EDSS at week 48 
Relapse-free Week 24 in trial 
Relapse-free week 48 
Annualised relapse rate week 24 
Annualised relapse rate week 48 
MSFC week 24 
 
Anti-drug antibodies week 0-108  
Serious Adverse events 
Other adverse events 
35 
40.3 ± 12.0 
68.6% 
7.4 ± 6.70 
1.5 ± 1.38 
1.2 ± 2.08 
7.0 ± 8.07 
 
1.76 ± 3.62 
1.3 ± 2.79 
1.5 ± 4.06 
2.77 ± 1.42 











41.7 ± 10.2 
68.6% 
8.5 ± 7.81 
1.4 ± 1.26 
1.1 ± 2.64 
8.5 ± 10.53 
 
1.82 ± 3.31 
1.0 ± 2.37 
1.3 ± 0.65 
2.91 ± 0.99 











43.1 ± 10.1 
64.7% 
9.4 ± 6.96 
1.3 ± 0.51 
0.5 ± 0.93 
7.8 ± 9.21 
 
0.71 ± 1.10 
0.7 ± 1.51 
0.4 ± 0.65 
2.78 ± 1.33 











40.8 ± 10.8 
79.4% 
9.2 ± 7.49 
1.4 ± 0.73 
1.1 ± 1.91 
6.6 ± 7.92 
 
1.24 ± 2.00 
1.2 ± 2.42 
1.8 ± 6.04 
2.62 ± 1.25 











40.8 ± 11.1 
58.3% 
8.9 ± 9.52 
1.2 ± 0.56 
1.4 ± 2.60 
9.0 ± 11.90 
 
1.48 ± 2.83 
1.7 ± 4.28 
2.8 ± 6.04 
2.17 ± 1.43 










Table 1B Dose of atacicept 
Atacicept NCT00642902 trial Placebo 25mg  75mg  150mg 
Number 
Age (Year) 
Sex (% Female) 
Time from First attack (Years) 
Mean Relapses past year  
Baseline No. T1 Gd+ lesions 
Volume T2 lesions (mm3) 
EDSS baseline 
 
T1 Gd+ lesion per scan [95% CI] 
Lesions/participant Week 24 
Lesion/participant Week 36 
Relapses in blinded trial 
Relapse Free in trial 




7.5 ± 7.5 
N.R. 
2.2 ± 4.1 
7531 ± 9813 
2.49 ± 1.19 
 
3.07 [1.40-6.77] 
0.83 ± 1.70 





37.5 ± 8.5 
54.0% 
8.6 ± 7.0 
N.R. 
1.1 ± 2.1 
5574 ± 8451 
2.83 ± 1.31 
 
2.26 [0.09-5.27] 
1.50 ± 2.79 





38.0 ± 10.1 
68.8% 
7.9 ± 7.2 
N.R. 
1.4 ± 3.7 
7537 ± 11297 









37.7 ± 10.5 
70.8% 
6.9 ± 6.8 
N.R. 
1.5 ± 4.7 
6092 ± 0326 
2.54 ± 1.28 
 
2.49 [1.18-5.27] 
1.54 ± 2.94 























            
 
FIGURE 3 
 
